Replies to post #3940 on PROTALIX BIOTHERAPEUTICS, INC. (PLX)

[midastouch017]

Bottom Line
I expect Protalix to thrive after the commencement of the commercialization of Elfabrio. The prevalence of Fabry disease and the growing market size of the disease treatment options means significant value will be placed on Elfabrio as a potential alternative. Additionally, Protalix has greater leverage with Elfabrio since it is handling the manufacturing part of the drug substance which is essential in its agreement with Chiesi. I believe this stock is a hold pending the successful commercialization of the drug post FDA approval.